Simone Meini1, Carlo Tascini2, Marco Cei3, Emanuela Sozio4, Gian Maria Rossolini5,6. 1. Internal Medicine Unit, Santa Maria Annunziata Hospital, Florence, Italy. simonemeini2@gmail.com. 2. First Division of Infectious Diseases, Cotugno Hospital, Naples, Italy. 3. Internal Medicine Unit, Cecina Hospital, Cecina, Italy. 4. Emergency Department, North-West District Tuscany Health Care, Spedali Riuniti, Leghorn, Italy. 5. Clinical Microbiology and Virology Unit, Florence Careggi University Hospital, Florence, Italy. 6. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Abstract
BACKGROUND: Enterobacterales are among the most common causes of bacterial infections in the community and among hospitalized patients, and multidrug-resistant (MDR) strains have emerged as a major threat to human health. Resistance to third-generation cephalosporins is typical of MDRs, being mainly due to the production of extended spectrum β-lactamases or AmpC-type β-lactamases. OBJECTIVE: The objective of this paper is to review the epidemiological impact, diagnostic issues and treatment options with AmpC producers. FINDINGS: AmpC enzymes encoded by resident chromosomal genes (cAmpCs) are produced by some species (e.g., Enterobacter spp., Citrobacter freundii, Serratia marcescens), while plasmid-encoded AmpCs (pAmpCs) can be encountered also in species that normally do not produce cAmpCs (e.g., Salmonella enterica, Proteus mirabilis, Klebsiella pneumoniae and Klebsiella oxytoca) or produce them at negligible levels (e.g., Escherichia coli). Production of AmpCs can be either inducible or constitutive, resulting in different resistance phenotypes. Strains producing cAmpCs in an inducible manner (e.g., Enterobacter spp.) usually appear susceptible to third-generation cephalosporins, which are poor inducers, but can easily yield mutants constitutively producing the enzyme which are resistant to these drugs (which are good substrates), resulting in treatment failures. pAmpCs are usually constitutively expressed. Production of pAmpCs is common in community-acquired infections, while cAmpC producers are mainly involved in healthcare-associated infections. CONCLUSIONS: To date, there is no conclusive evidence about the most appropriate treatment for AmpC-producing Enterobacterales. Carbapenems are often the preferred option, especially for severe infections in which adequate source control is not achieved, but cefepime is also supported by substantial clinical evidences as an effective carbapenem-sparing option.
BACKGROUND: Enterobacterales are among the most common causes of bacterial infections in the community and among hospitalized patients, and multidrug-resistant (MDR) strains have emerged as a major threat to human health. Resistance to third-generation cephalosporins is typical of MDRs, being mainly due to the production of extended spectrum β-lactamases or AmpC-type β-lactamases. OBJECTIVE: The objective of this paper is to review the epidemiological impact, diagnostic issues and treatment options with AmpC producers. FINDINGS:AmpC enzymes encoded by resident chromosomal genes (cAmpCs) are produced by some species (e.g., Enterobacter spp., Citrobacter freundii, Serratia marcescens), while plasmid-encoded AmpCs (pAmpCs) can be encountered also in species that normally do not produce cAmpCs (e.g., Salmonella enterica, Proteus mirabilis, Klebsiella pneumoniae and Klebsiella oxytoca) or produce them at negligible levels (e.g., Escherichia coli). Production of AmpCs can be either inducible or constitutive, resulting in different resistance phenotypes. Strains producing cAmpCs in an inducible manner (e.g., Enterobacter spp.) usually appear susceptible to third-generation cephalosporins, which are poor inducers, but can easily yield mutants constitutively producing the enzyme which are resistant to these drugs (which are good substrates), resulting in treatment failures. pAmpCs are usually constitutively expressed. Production of pAmpCs is common in community-acquired infections, while cAmpC producers are mainly involved in healthcare-associated infections. CONCLUSIONS: To date, there is no conclusive evidence about the most appropriate treatment for AmpC-producing Enterobacterales. Carbapenems are often the preferred option, especially for severe infections in which adequate source control is not achieved, but cefepime is also supported by substantial clinical evidences as an effective carbapenem-sparing option.
Authors: Marco M D'Andrea; Elisabetta Nucleo; Francesco Luzzaro; Tommaso Giani; Roberta Migliavacca; Francesca Vailati; Vesselina Kroumova; Laura Pagani; Gian Maria Rossolini Journal: Antimicrob Agents Chemother Date: 2006-02 Impact factor: 5.191
Authors: Francesco Luzzaro; Gioconda Brigante; Marco Maria D'Andrea; Beatrice Pini; Tommaso Giani; Elisabetta Mantengoli; Gian Maria Rossolini; Antonio Toniolo Journal: Int J Antimicrob Agents Date: 2008-12-17 Impact factor: 5.283
Authors: J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu Journal: Ann Intern Med Date: 1991-10-15 Impact factor: 25.391
Authors: Alessandra Piccirilli; Alberto Antonelli; Marco Maria D'Andrea; Sabrina Cherubini; Mariagrazia Perilli; Gian Maria Rossolini Journal: Antimicrob Agents Chemother Date: 2022-08-30 Impact factor: 5.938